<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20120215009014N629</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-11-12</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>Effect of neuromuscular electrical stimulation, light resistance training, and their combination versus control group on cellular markers, and hemodynamic stability in hemodialysis patients</public_title>
      <acronym></acronym>
      <scientific_title>Effect of neuromuscular electrical stimulation, light resistance training, and their combination versus control group on markers of mitochondrial biogenesis, cellular pyroptosis, and hemodynamic stability in hemodialysis patients with cardiorenal syndrome: a randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-12-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/94726</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random allocation of patients to intervention and control groups by lottery. For this purpose, we prepare two sheets, write "intervention" on one and "control" on the other. Then, with each patient's visit, one of the sheets is randomly taken and the patient is assigned to the intervention or control group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Hemodialysis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group 1: Routine care and treatment for hemodialysis patients, plus a light resistance training program (including exercises for the biceps, triceps, knee flexion, hamstrings, glutes, quadriceps, and calf/ankle muscles), three sessions per week for 8 weeks. Intervention 2: Intervention Group 2: Routine care and treatment for hemodialysis patients, plus neuromuscular electrical stimulation (NMES) applied to the quadriceps muscles bilaterally (using an NMES device at a frequency of 50 Hz; 10 seconds of stimulation followed by 20-second intervals, for a total duration of 20–30 minutes), three sessions per week for 8 weeks. Intervention 3: Intervention Group 3: Routine care and treatment for hemodialysis patients, plus both interventions: the light resistance training program (including exercises for the biceps, triceps, knee flexion, hamstrings, glutes, quadriceps, and calf/ankle muscles) combined with neuromuscular electrical stimulation (NMES) applied to the quadriceps muscles bilaterally (using an NMES device). A frequency of 50 Hz applied for 10 seconds, with 20-second intervals, for a duration of 20 to 30 minutes, three sessions per week, over a period of 8 weeks. Intervention 4: Control group: Routine care and treatment for hemodialysis patients.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is It depends on the situation and the results of the study as well as the approval of the financial supporting organization.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Samira Mehrabipour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Islamic Azad University, Hamadan Branch, Professor Moosivand Ave</address>
        <city>Hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6518115743</zip>
        <telephone>+98 81 3949 4000</telephone>
        <email>samira.mehrabipour@iau.ac.ir</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Kamal Azizbeigi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Islamic Azad University, Hamadan Branch, Professor Moosivand Ave</address>
        <city>Hamadan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6518115743</zip>
        <telephone>+98 81 3949 4000</telephone>
        <email>kazizbeigi@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 18 to 75 years;
Chronic kidney disease with regular hemodialysis for at least three months;
Cardiorenal syndrome;
Ability to perform exercise movements and receive neuromuscular electrical stimulation (NMES).</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Chest pain, abnormal shortness of breath, or suspected arrhythmia;
Dizziness or symptomatic hypotension;
Skin burns or infections at the site of electrical stimulation.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I95.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Hypotension of hemodialysis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group 1: Routine care and treatment for hemodialysis patients, plus a light resistance training program (including exercises for the biceps, triceps, knee flexion, hamstrings, glutes, quadriceps, and calf/ankle muscles), three sessions per week for 8 weeks.</i_keyword>
      <i_keyword>Intervention Group 2: Routine care and treatment for hemodialysis patients, plus neuromuscular electrical stimulation (NMES) applied to the quadriceps muscles bilaterally (using an NMES device at a frequency of 50 Hz; 10 seconds of stimulation followed by 20-second intervals, for a total duration of 20–30 minutes), three sessions per week for 8 weeks.</i_keyword>
      <i_keyword>Intervention Group 3: Routine care and treatment for hemodialysis patients, plus both interventions: the light resistance training program (including exercises for the biceps, triceps, knee flexion, hamstrings, glutes, quadriceps, and calf/ankle muscles) combined with neuromuscular electrical stimulation (NMES) applied to the quadriceps muscles bilaterally (using an NMES device). A frequency of 50 Hz applied for 10 seconds, with 20-second intervals, for a duration of 20 to 30 minutes, three sessions per week, over a period of 8 weeks.</i_keyword>
      <i_keyword>Control group: Routine care and treatment for hemodialysis patients.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>PGC-1α levels. Timepoint: Before the intervention and at the end of the eighth week. Method of measurement: Measured via ELISA in cell samples.</prim_outcome>
      <prim_outcome>SIRT1 enzymatic activity. Timepoint: Before the intervention and at the end of the eighth week. Method of measurement: Measured via a fluorometric enzymatic activity assay.</prim_outcome>
      <prim_outcome>NLRP3 levels. Timepoint: Before the intervention and at the end of the eighth week. Method of measurement: Measured via ELISA in cell samples.</prim_outcome>
      <prim_outcome>Caspase-1 enzymatic activity. Timepoint: Before the intervention and at the end of the eighth week. Method of measurement: Measured via an enzymatic activity assay.</prim_outcome>
      <prim_outcome>IL-18 concentration. Timepoint: before the intervention and at the end of the eighth week. Method of measurement: Measured via ELISA in blood serum samples.</prim_outcome>
      <prim_outcome>Blood pressure. Timepoint: Before the intervention and at the end of the eighth week. Method of measurement: Measured using a sphygmomanometer.</prim_outcome>
      <prim_outcome>BUN concentration. Timepoint: Before the intervention and at the end of the eighth week. Method of measurement: Measured via the enzymatic urease method in blood serum samples.</prim_outcome>
      <prim_outcome>Serum creatinine concentration. Timepoint: Before the intervention and at the end of the eighth week. Method of measurement: Measured via a standard enzymatic method in blood serum samples.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-10-24</approval_date>
        <contact_name>Ethics Committee of Islamic Azad University, Hamadan Branch</contact_name>
        <contact_address>Vice-chancellor for Research and Technology, Islamic Azad University, Hamadan Branch, Professor Moosivand Ave Hamadan Hamadan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
